BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Bausch Health Companies Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$6.32+0.02 (+0.32%)
Close on Oct 19, 2026
- Market cap
- $2.39B
- P/E (TTM)
- –
- Dividend yield
- –
Bausch Health Companies Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch + Lomb | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B | $3.42B | $3.78B | – | – | – | 49.7% | +6.5% |
| Salix | $2.58B | $2.33B | $2.25B | $2.09B | $2.07B | $1.90B | $2.02B | $1.75B | $1.57B | $1.53B | 25.1% | +10.5% |
| International | $1.13B | $1.11B | $1.07B | $988.00M | $1.17B | $1.18B | $1.15B | – | – | – | 11.0% | +1.9% |
| Diversified | $937.00M | $950.00M | $943.00M | $978.00M | $1.12B | – | – | – | – | – | 9.1% | -1.4% |
| Solta Medical | $518.00M | $440.00M | $347.00M | $300.00M | $308.00M | $253.00M | – | – | – | – | 5.0% | +17.7% |
| U.S. Diversified Products | – | – | – | – | – | – | – | – | $1.38B | $1.92B | – | – |
| Branded Rx | – | – | – | – | – | – | – | – | $2.48B | $2.83B | – | – |
| Bausch + Lomb/ International | – | – | – | – | – | – | – | $4.66B | $4.80B | $4.86B | – | – |
| Diversified | – | – | – | $978.00M | $1.12B | $1.27B | $1.09B | $1.35B | $1.64B | $2.34B | – | – |
| Dermatology | – | – | – | – | $564.00M | $548.00M | $560.00M | $617.00M | $721.00M | $949.00M | – | – |
| Bausch + Lomb/International | – | – | – | – | – | $4.41B | $4.74B | $4.66B | $4.80B | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix | $1.93B | $1.60B | $1.55B | $1.49B | $1.49B | $1.34B | $1.35B | $1.15B | $935.00M | $946.00M | +20.2% |
| Bausch + Lomb | $1.13B | $1.11B | $980.00M | $874.00M | $958.00M | $909.00M | $1.12B | – | – | – | +1.5% |
| Diversified | $627.00M | $626.00M | $586.00M | $612.00M | $722.00M | – | – | – | – | – | +0.2% |
| International | $334.00M | $376.00M | $335.00M | $324.00M | $403.00M | $386.00M | $352.00M | – | – | – | -11.2% |
| Solta Medical | $232.00M | $213.00M | $161.00M | $135.00M | $167.00M | $131.00M | – | – | – | – | +8.9% |
| U.S. Diversified Products | – | – | – | – | – | – | – | – | $994.00M | $1.52B | – |
| Branded Rx | – | – | – | – | – | – | – | – | $1.36B | $1.52B | – |
| Bausch + Lomb/ International | – | – | – | – | – | – | – | $1.33B | $1.41B | $1.46B | – |
| Diversified | – | – | – | $612.00M | $722.00M | $814.00M | $801.00M | $1.01B | $1.12B | $1.71B | – |
| Dermatology | – | – | – | – | $265.00M | $228.00M | $216.00M | $257.00M | $333.00M | $408.00M | – |
| Bausch + Lomb/International | – | – | – | – | – | $1.16B | $1.33B | $1.33B | $1.41B | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $10.16B | $9.52B | $8.66B | $8.03B | $8.33B | $7.92B | $8.49B | $8.27B | $8.60B | $9.54B | 98.9% | +6.7% |
| Pharmaceuticals | $4.75B | $4.40B | $3.91B | $3.64B | $3.74B | $3.68B | $4.08B | $4.03B | $4.38B | $5.17B | 46.2% | +8.0% |
| Devices | $2.44B | $2.24B | $2.00B | $1.87B | $1.90B | $1.57B | $1.72B | $1.64B | $1.53B | $1.50B | 23.8% | +8.9% |
| OTC | $2.01B | $1.90B | $1.80B | $1.62B | $1.54B | $1.43B | $1.45B | $1.41B | $1.53B | $1.58B | 19.6% | +5.5% |
| Branded and Other generics | $962.00M | $979.00M | $960.00M | $892.00M | $1.14B | $1.25B | $1.25B | $1.19B | $1.16B | $1.29B | 9.4% | -1.7% |
| Other revenues | $110.00M | $107.00M | $94.00M | $99.00M | $106.00M | $103.00M | $112.00M | $109.00M | $129.00M | $138.00M | 1.1% | +2.8% |
| Other revenues | $110.00M | $107.00M | $94.00M | $99.00M | $106.00M | $103.00M | $112.00M | $109.00M | $129.00M | $138.00M | 1.1% | +2.8% |
| Price Appreciation Credit | $18.00M | $18.00M | $11.00M | $10.00M | $17.00M | $15.00M | $11.00M | $31.00M | – | – | 0.2% | 0.0% |
| Other revenues | – | – | – | – | – | – | – | – | $129.00M | $138.00M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | $6.14B | $5.77B | $5.19B | $4.84B | $4.89B | $4.79B | $5.16B | $5.01B | $5.23B | $6.25B | 59.8% | +6.4% |
| Other | $1.15B | $1.08B | $1.01B | $887.00M | $1.07B | $1.11B | $995.00M | $1.13B | $1.26B | $1.30B | 11.2% | +6.5% |
| China | $493.00M | $496.00M | $441.00M | $413.00M | $490.00M | $341.00M | $368.00M | $361.00M | $331.00M | $300.00M | 4.8% | -0.6% |
| Canada | $417.00M | $402.00M | $366.00M | $351.00M | $343.00M | $331.00M | $339.00M | $319.00M | $326.00M | $320.00M | 4.1% | +3.7% |
| Poland | $382.00M | $350.00M | $319.00M | $278.00M | $280.00M | $238.00M | $231.00M | $218.00M | $201.00M | $140.00M | 3.7% | +9.1% |
| Mexico | $278.00M | $315.00M | $322.00M | $276.00M | $256.00M | $225.00M | $228.00M | $211.00M | $201.00M | $189.00M | 2.7% | -11.7% |
| France | $249.00M | $230.00M | $214.00M | $203.00M | $208.00M | $179.00M | $201.00M | $205.00M | $188.00M | $186.00M | 2.4% | +8.3% |
| South Korea | $234.00M | $146.00M | $93.00M | $77.00M | $76.00M | $68.00M | – | – | – | – | 2.3% | +60.3% |
| Russia | $198.00M | $161.00M | $148.00M | $181.00M | $160.00M | $137.00M | $180.00M | $154.00M | $200.00M | $165.00M | 1.9% | +23.0% |
| Japan | $192.00M | $188.00M | $194.00M | $200.00M | $230.00M | $226.00M | $241.00M | $226.00M | $223.00M | $232.00M | 1.9% | +2.1% |
| Germany | $176.00M | $159.00M | $152.00M | $147.00M | $154.00M | $144.00M | $150.00M | $170.00M | $157.00M | $157.00M | 1.7% | +10.7% |
| United Kingdom | $141.00M | $135.00M | $125.00M | $115.00M | $116.00M | $86.00M | $115.00M | $117.00M | $108.00M | $104.00M | 1.4% | +4.4% |
| Spain | $109.00M | $99.00M | $92.00M | $84.00M | $88.00M | $78.00M | $86.00M | $83.00M | $77.00M | $70.00M | 1.1% | +10.1% |
| Italy | $106.00M | $94.00M | $86.00M | $76.00M | $80.00M | $71.00M | $85.00M | $85.00M | $78.00M | $72.00M | 1.0% | +12.8% |
| Brazil | – | – | – | – | – | – | – | – | $96.00M | $105.00M | – | – |
| Australia | – | – | – | – | – | – | – | – | $149.00M | $176.00M | – | – |
| Egypt | – | – | – | – | $156.00M | $243.00M | $218.00M | $178.00M | $152.00M | $196.00M | – | – |
From the segment and revenue-disaggregation notes of Bausch Health Companies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.